c-MET: an exciting new target for anticancer therapy

Por de Bono, Johann S., Yap, Timothy A.
Publicado em 2011

Future directions in the evaluation of c-MET-driven malignancies

Por de Bono, Johann S., Yap, Timothy A.
Publicado em 2011

CCR new strategies: Targeting the androgen receptor signaling pathway in metastatic prostate cancer

Por Attard, Gerhardt, Richards, Juliet, de Bono, Johann S
Publicado em 2011

Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?

Por Yap, Timothy A, Swanton, Charles, de Bono, Johann S
Publicado em 2012

Reappraisal of glucocorticoids in castrate-resistant prostate cancer

Por Sartor, Oliver, Parker, Christopher C, de Bono, Johann
Publicado em 2014

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key

Por de Bono, Johann S, Tolcher, Anthony W, Rowinsky, Eric K
Publicado em 2003

Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies

Por Attard, Gerhardt, Clark, Jeremy, Cooper, Colin S., De Bono, Johann S.
Publicado em 2010

Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer

Por Sharp, Adam, Welti, Jonathan, Blagg, Julian, de Bono, Johann S.
Publicado no Clin Cancer Res (2016)

The promise of circulating tumor cell analysis in cancer management

Por Mateo, Joaquin, Gerlinger, Marco, Rodrigues, Daniel Nava, de Bono, Johann S
Publicado no Genome Biol (2014)

Novel Therapeutic Strategies for Metastatic Prostate Cancer in the Post-Docetaxel Setting

Por Sartor, Oliver, Michels, Ross M., Massard, Christophe, de Bono, Johann Sebastian
Publicado em 2011

Revisiting the Role of Antiandrogen Strategies in Ovarian Cancer

Por Papadatos-Pastos, Dionysis, Dedes, Konstantin J., de Bono, Johann S., Kaye, Stanley B.
Publicado em 2011

Chromatin to clinic: The molecular rationale for PARP1 inhibitor function

Por Knudsen, Karen E., de Bono, Johann S., Rubin, Mark A., Feng, Felix Y.
Publicado no Mol Cell (2015)

Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to b...

Por A’Hern Roger, DeBono Johann, Sandhu Shahneen, Kalaitzaki Eletheria, Usdin Martine, Hall Emma E
Publicado em 2011-12-01

Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to b...

Por A’Hern, Roger, DeBono, Johann, Sandhu, Shahneen, Kalaitzaki, Eletheria, Usdin, Martine, Hall, Emma E
Publicado em 2011

Circulating Tumor Cell Number as a Prognostic Marker in Progressive Castration-Resistant Prostate Cancer: Use in Clinical Practice and Clinical Trials

Por Scher, Howard I., Jia, Xiaoyu, de Bono, Johann S., Fleisher, Martin, Pienta, Kenneth J., Raghavan, Derek, Heller, Glenn
Publicado em 2009

Perceptions and Referral Trends into Phase I Oncology Trials: Results of a Clinical Survey

Por Brunetto, Andre, Olmos, David, Arkenau, Hendrik-Tobias, Tan, Daniel, Yap, Timomy, de Bono, Johann, Barriuso, Jorge, Kaye, Stan
Publicado em 2011

Unbiased and Automated Identification of a Circulating Tumour Cell Definition That Associates with Overall Survival

Por Ligthart, Sjoerd T., Coumans, Frank A. W., Attard, Gerhardt, Mulick Cassidy, Amy, de Bono, Johann S., Terstappen, Leon W. M. M.
Publicado em 2011

Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy

Por Halabi, Susan, Armstrong, Andrew J., Sartor, Oliver, de Bono, Johann, Kaplan, Ellen, Lin, Chen-Yen, Solomon, Nicole C., Small, Eric J.
Publicado em 2013

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors

Por Spicer, James, Irshad, Sheeba, Ang, Joo Ern, Enting, Deborah, Kristeleit, Rebecca, Uttenreuther-Fischer, Martina, Pemberton, Karine, Pelling, Katy, Schnell, David, de Bono, Johann
Publicado no Cancer Chemother Pharmacol (2016)

The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population

Por Heller, Glenn, Fizazi, Karim, McCormack, Robert, Molina, Arturo, MacLean, David, Webb, Iain J, Saad, Fred, de Bono, Johann S, Scher, Howard I
Publicado no Clin Cancer Res (2016)